Dundee, UK – Tay Therapeutics is proud to be featured in the Summer 2025 edition of European Biopharmaceutical Review (EBR). The article highlights Tay’s strategic evolution from a seed-funded spinout to a capital-efficient Biotech delivering high-impact innovation across inflammatory and rare genetic diseases.

In just over four years, Tay has achieved key milestones:

• Licensing two BET inhibitor drug candidates to VYNE Therapeutics

• Developing a ‘platform-in-a-pill’ oral gene therapy, now entering IND-enabling studies

• Increased company valuation more than 20-fold

The article also previews the upcoming launch of Hawkhill Therapeutics – a new venture from the Tay team, focused on developing oral, muscle-sparing obesity therapies to address a major unmet need in global metabolic health.

CEO Andrew Woodland will attend BIO 2025 in Boston, meeting prospective licensing partners and investors. Interested parties are invited to connect via the BIO partnering platform or reach out directly.

📖 Read the full article in EBR: [https://lnkd.in/eG4CNjGD]

🔗 See our LinkedIn announcement: TayLinkedIn